MedTrace Logo

Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS

NCT02686268 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 128

Last updated 2021-07-08

No results posted yet for this study

Summary

This research study is being performed to better understand a specific form of Amyotrophic Lateral Sclerosis (ALS) caused by a mutation (or abnormality) of the C9ORF72 gene. This mutation is the most common genetic cause of ALS, and is present in 40% of ALS patients with a family history of ALS and 5-10% of ALS patients without a family history of ALS.

Conditions

  • C9ORF72 Amyotrophic Lateral Sclerosis (ALS)

Sponsors & Collaborators

  • Cedars-Sinai Medical Center

    collaborator OTHER

  • UMC Utrecht

    collaborator OTHER

  • Johns Hopkins University

    collaborator OTHER

  • Massachusetts General Hospital

    collaborator OTHER

  • University of Massachusetts, Amherst

    collaborator OTHER

  • Biogen

    collaborator INDUSTRY

  • ALS Association

    collaborator OTHER

  • Columbia University

    collaborator OTHER

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Timothy M Miller, MD, PhD · Washington University School of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2017-12-31
Completion
2018-10-02

Countries

  • United States
  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02686268 on ClinicalTrials.gov